The efficacy advantage of evolocumab (AMG 145) dosed at 140Â mg every 2Â weeks versus 420Â mg every 4Â weeks in patients with hypercholesterolemia: Evidence from a meta-analysis

Article ID	Journal	Published Year	Pages	File Type
5679016	European Journal of Internal Medicine	2017	9 Pages	PDF

Abstract

Evolocumab administered at 140Â mg Q2W was more effective than the 420Â mg Q4W dosage at lowering lipid concentrations, especially in patients who concomitantly received stable statin therapy.

Keywords

Evolocumab VLDL-C HoFH RCTs CHD HDL-C PCSK9 LDL-C LDLR ALT Q2W Q4W TEAE Randomized controlled trials AST Aspartate aminotransferase Alanine aminotransferase standard deviation coronary heart disease cardiovascular disease Triglycerides Relative risk CVD non-HDL-C confidence interval Meta-analysis mean difference Homozygous familial hypercholesterolemia Proprotein convertase subtilisin/kexin type 9 total cholesterol high density lipoprotein cholesterol Very low density lipoprotein cholesterol Non-high-density lipoprotein cholesterol low density lipoprotein cholesterol low density lipoprotein receptor

Related Topics

Health Sciences Medicine and Dentistry Medicine and Dentistry (General)

The efficacy advantage of evolocumab (AMG 145) dosed at 140Â mg every 2Â weeks versus 420Â mg every 4Â weeks in patients with hypercholesterolemia: Evidence from a meta-analysis

Authors

Xiao-Xiao He, Rong Zhang, Pei-Yuan Zuo, Yu-Wei Liu, Xiang-Nan Zha, Sheng-Shuai Shan, Cheng-Yun Liu,